Photo taken from ESMO/LinkedIn
Jul 31, 2024, 07:32
Breaking Science in Gastrointestinal Cancers with David Tougeron – ESMO
ESMO shared on LinkedIn:
“For ESMO members: Breaking Science in Gastrointestinal Cancers.
David Tougeron discusses Pembrolizumab combo with XELOX and bevacizumab for pMMR/MSS mCRC and high immune infiltrate.
Discover this video and more in the series on OncologyPRO now.”
Pembrolizumab combo with XELOX and bev for pMMR/MSS mCRC and high immune infiltrate
Speaker: David Tougeron
Abstract discussed: Pembrolizumab in combination with xelox and bevacizumab in patients with microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC) and a high immune infiltrate.
Source: ESMO/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 30, 2025, 23:21
Mar 30, 2025, 18:52
Mar 30, 2025, 18:31
Mar 30, 2025, 18:04